Burak Tatar1, Gökhan Boyraz2, İlker Selçuk3, Alper K Doğan4, Alp Usubütün5, Zafer Selçuk Tuncer2. 1. Department of Gynecologic Oncology, Süleyman Demirel University School of Medicine, Isparta, Turkey. 2. Department of Gynecologic Oncology, Hacettepe University School of Medicine, Ankara, Turkey. 3. Department of Gynecologic Oncology, Zekai Tahir Burak Maternity and Teaching Hospital, Ankara, Turkey. 4. Onkosel Biotechnology, Hacettepe University Technopolis, Ankara, Turkey. 5. Department of Pathology, Hacettepe University School of Medicine, Ankara, Turkey.
Abstract
OBJECTIVE: An alternative approach to the current therapy of ovarian carcinoma is the individualization of treatment by determining the sensitivity of tumoral tissue to chemotherapeutic agents before the initiation of chemotherapy. The objectives of the study are to determine the efficacy of in vitro chemosensitivity assays in ovarian carcinoma and to measure the correlation of three leading assays. MATERIAL AND METHODS: Fresh tumoral tissue samples of 26 newly diagnosed primary ovarian cancer patients were studied with 3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolyum bromide (MTT) assay, adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) and differential staining cytotoxicity (DISC) assays. Chemosensitivity of tumors were studied for paclitaxel, carboplatin, docetaxel, topotecan, gemcitabine, and doxorubicin with each of the three assays. Subgroup analysis was performed for stage, grade, and histologic type. RESULTS: The in vitro chemosensitivity results of MTT, ATP, and DISC assays were found to be similar. The subgroups in which in vitro assays would be more useful were encountered for patients with advanced stage and serous histology ovarian carcinoma. CONCLUSIONS: In vitro chemosensitivity can be determined in ovarian carcinoma with ATP, MTT, or DISC assays before the initiation of chemotherapy. These three assays correlate well with each other and are particularly useful for serous and advanced cancers. Large prospective studies comparing standard versus assay-directed therapy with an endpoint of overall survival are required before routine clinical utilization of these assays.
OBJECTIVE: An alternative approach to the current therapy of ovarian carcinoma is the individualization of treatment by determining the sensitivity of tumoral tissue to chemotherapeutic agents before the initiation of chemotherapy. The objectives of the study are to determine the efficacy of in vitro chemosensitivity assays in ovarian carcinoma and to measure the correlation of three leading assays. MATERIAL AND METHODS: Fresh tumoral tissue samples of 26 newly diagnosed primary ovarian cancerpatients were studied with 3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolyum bromide (MTT) assay, adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) and differential staining cytotoxicity (DISC) assays. Chemosensitivity of tumors were studied for paclitaxel, carboplatin, docetaxel, topotecan, gemcitabine, and doxorubicin with each of the three assays. Subgroup analysis was performed for stage, grade, and histologic type. RESULTS: The in vitro chemosensitivity results of MTT, ATP, and DISC assays were found to be similar. The subgroups in which in vitro assays would be more useful were encountered for patients with advanced stage and serous histology ovarian carcinoma. CONCLUSIONS: In vitro chemosensitivity can be determined in ovarian carcinoma with ATP, MTT, or DISC assays before the initiation of chemotherapy. These three assays correlate well with each other and are particularly useful for serous and advanced cancers. Large prospective studies comparing standard versus assay-directed therapy with an endpoint of overall survival are required before routine clinical utilization of these assays.
Entities:
Keywords:
ATP; DISC; MTT; Ovarian cancer; in vitro chemosensitivity
Authors: Rebecca Previs; Charles A Leath; Robert L Coleman; Thomas J Herzog; Thomas C Krivak; Stacey L Brower; Chunqiao Tian; Angeles Alvarez Secord Journal: Gynecol Oncol Date: 2015-05-30 Impact factor: 5.482
Authors: Vera Loizzi; John K Chan; Kathryn Osann; Fabio Cappuccini; Philip J DiSaia; Michael L Berman Journal: Am J Obstet Gynecol Date: 2003-11 Impact factor: 8.661
Authors: Michelle A Glasgow; Peter Argenta; Juan E Abrahante; Mihir Shetty; Shobhana Talukdar; Paula A Croonquist; Mahmoud A Khalifa; Timothy K Starr Journal: Int J Mol Sci Date: 2019-04-30 Impact factor: 5.923